Pharmaceuticals, Biotechnology and Life Sciences
Alvotech said in a Monday press release it has appointed Joseph Edward McClellan as its new Chief Scientific Officer, who will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.
Novartis will present results from its trial designated Mnaleesa-3, which showed that ribociclib branded as Kisqali has achieved statistically significant improvement in overall survival (OS), which is – according to Novartis – the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials — consistently demonstrating approximately 30% reduction in the risk of death.
Elevar Therapeutics presented a study at ESMO, showing the potential of rivoceranib to treat patients with late-stage gastric cancer, which was is the first multinational phase 3 study after rivoceranib’s approval in China, said Dr. Steven Norton, Elevar Therapeutics’ Vice President of Clinical Development.
Researchers presented results from Adlai Nortye’s investigational, potentially first in class oral EP4 antagonist, two dose levels of AN0025 in combination with the standard of care for locally advanced rectal cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by MRI at ESMO.
Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer
Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.
Synairgen is confident to get a positive outcome in Part 2 study of Phase 2 trial of its antiviral therapy for Chronic Obstructive Pulmonary Disorder (COPD) patients, in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection, after the first part showed positive results.
Sygnature Discovery has developed an AR molecular visualisation prototype, meaning that scientists could soon be rotating virtual molecules in the world around them.
The FDA granted the approval of Jynneos for the prevention of monkeypox disease, to Bavarian Nordic A/S, and it granted the application Priority Review, it said Tuesday in a press release.
Belgian Sequana Medical has enrolled the first patient in the North American pivotal study of the alfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis.